"In contrast, DCVax has achieved clinical benefits (i.e.longer delay in disease progression and longer extension of survival than with standard of care treatment) in over 80% of the patients who have received DCVax in clinical trials to date."
I presume they are talking about the earlier phase trials. You can't possibly know those details for the p3 unless you're unblinded.
Market Data 
Markets 
AI
